Clinical bottom line
Penicillin allergy delabeling is increasingly recognized as a critical component of antimicrobial stewardship, with updated evidence supporting safe and effective strategies to remove inaccurate penicillin allergy labels. Pharmacist-driven programs and proactive quality improvement initiatives demonstrate feasibility without routine skin testing or oral challenges in low-risk patients. Delabeling reduces unnecessary use of broad-spectrum antibiotics, lowers healthcare costs, and improves patient outcomes. However, implementation requires multidisciplinary collaboration and careful patient selection (Banerji et al., 2023; Song et al., 2021; McDonald et al., 2025).
What the evidence shows
Banerji et al. (2023) provide updated drug allergy practice parameters emphasizing that most reported penicillin allergies are not true IgE-mediated hypersensitivities. They recommend risk stratification to identify patients eligible for direct oral amoxicillin challenges without prior skin testing, streamlining delabeling efforts.
Song et al. (2021) evaluated a pharmacist-driven penicillin allergy delabeling pilot program that omitted skin testing and oral challenges, relying instead on detailed history and risk assessment. The program successfully delabeled a significant proportion of patients with low-risk histories, demonstrating feasibility and safety in an outpatient setting.
McDonald et al. (2025) report on a proactive quality improvement project incorporating electronic health record alerts and multidisciplinary collaboration to identify and delabel inappropriate penicillin allergies. Their approach improved delabeling rates and antibiotic prescribing patterns, highlighting the importance of system-level interventions.
White et al. (2023) review penicillin delabeling strategies, underscoring that delabeling leads to increased use of first-line beta-lactams, reduced adverse drug events, and decreased antimicrobial resistance.
Raja et al. (2026) discuss bridging the evidence-practice gap by integrating penicillin allergy delabeling into antimicrobial stewardship programs, advocating for standardized protocols and clinician education to enhance uptake.
Caveats and uncertainty
While direct oral challenge without skin testing is effective in low-risk patients, high-risk individuals still require allergist evaluation and testing, limiting universal applicability.
Variability in risk assessment tools and definitions of low risk may affect consistency across settings.
Long-term follow-up data on delabeling durability and impact on clinical outcomes remain limited.
Resource constraints and clinician knowledge gaps pose barriers to widespread implementation.
How this may change practice
Clinicians should incorporate structured penicillin allergy risk assessments into routine care, identifying candidates for direct oral amoxicillin challenge or referral for allergy testing.
Pharmacist-led delabeling initiatives can be integrated into outpatient and inpatient workflows to increase efficiency.
Antimicrobial stewardship programs should prioritize penicillin allergy delabeling as a key intervention to optimize antibiotic use.
Education of healthcare providers and patients about the safety and benefits of delabeling will support broader acceptance.
Health systems may adopt electronic health record alerts and standardized protocols to facilitate systematic delabeling efforts.